Observational studies have shown that colonoscopy reduces colorectal cancer (CRC) incidence and mortality in the general population. We aimed to conduct a meta-analysis quantifying the magnitude of protection by colonoscopy, with screening and diagnostic indications, against CRC in patients with non-malignant fi ndings and demonstrating the potentially more marked effect of screening over diagnostic colonoscopy.
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related death throughout the world ( 1 ) . By means of detection and subsequent resection of precancerous lesions and early-stage CRCs, screening is eff ective in reducing CRC incidence and mortality, which has already been demonstrated in trials with fecal occult blood test (2) (3) (4) (5) (6) and fl exible sigmoidoscopy (7) (8) (9) (10) (11) . Evidence for the eff ectiveness of colonoscopy screening in average-risk general population, however, is still limited as related large-scale randomized trials are still ongoing (12) (13) (14) (15) .
Since 2009, mounting evidence from observational studies has shown that colonoscopy screening is associated with reductions in both CRC incidence and mortality (16) (17) (18) (19) . However, colonoscopy screening programs have not been implemented in many European countries ( 20, 21 ) and most of the Asia-Pacifi c region ( 22 ) ; even the colonoscopy screening rates in the United States and Germany, where screening programs were introduced early this Colonoscopy Reduces Colorectal Cancer Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis century, were only 54% by 2013 ( 23 ) and ~20-30% by 2012 ( 24 ) , respectively. A great number of studies from the real-world settings in which indications for colonoscopy included both screening and diagnostic also supported the protective eff ect of colonoscopy in the general population (25) (26) (27) (28) (29) .
Two previous meta-analyses found signifi cant reductions in CRC mortality (and incidence) aft er (screening) colonoscopy ( 30, 31 ) , but the generalizability of the fi ndings in the general population is less than ideal due to the heterogeneity of the baseline population, as subjects with malignant fi ndings were enrolled in some included studies but not in others. Ranging from negative fi ndings, hyperplastic polyps, adenomas to serrated lesions, nonmalignant fi ndings at the index colonoscopy, which constitutes over 90% of the yield of colonoscopy in clinical practice ( 32, 33 ) , diff er with malignant fi ndings in the following aspects: non-malignant nature, mostly non-surgical treatment, longer surveillance interval, and better prognosis ( 34, 35 ) . We therefore aim to evaluate the magnitude of protection against CRC by colonoscopy, with screening and diagnostic indications, in patients with non-malignant fi ndings and further determine the potentially more marked eff ect of screening over diagnostic colonoscopy in the magnitude of reductions in CRC incidence and mortality.
METHODS

Search strategy
Th e meta-analysis was performed according to MOOSE statement (MOOSE Checklist is available in Supplementary Appendix A online) ( 36 ) . A comprehensive, computerized literature search was conducted in PubMed and EMBASE from the beginning of indexing for each database to 30 April 2015 by two reviewers (J.P. and L.X.) independently, with no restrictions in language. Th e search for relevant studies was performed using the following text words and corresponding Medical Subject Heading/Emtree terms: "colonoscopy or endoscopy" AND "colorectal, colon, rectum, or large bowel" AND "cancer, carcinoma, neoplasm, tumo(u)r, or adenocarcinoma" AND "relative risk(s), odds ratio(s), rate ratio(s), risk ratio(s), or hazard ratio(s)" AND "cohort, or case-control" (detailed search strategy is available in Supplementary Appendix B ). Abstracts from Digestive Disease Week (DDW) and United European Gastroenterology Week (UEGW) were searched manually. In addition, we searched for additional studies in reference lists of identifi ed articles.
Eligibility criteria
Th ree reviewers (J.P., L.X., and Y.-F.M.) independently evaluated all of the studies retrieved according to the eligibility criteria. Disagreements were resolved by consensus. Studies were included if they met all of the following criteria: (i) studies from which eff ect estimates assessing the eff ect of colonoscopy on CRC incidence and/or mortality in patients with non-malignant fi ndings vs. no colonoscopy were extractable (patients with non-malignant fi ndings were defi ned as a consecutive collection of both cases detected with non-malignant polyps and those with negative fi ndings at the index colonoscopy; the index colonoscopy was defi ned as the initial colonoscopy performed during the study period for either screening or diagnostic purpose); (ii) all of the participants with and without the exposure to colonoscopy are from the same population source; (iii) all of the participants had no history of CRC; (iv) all (or the vast majority) of the participants had no history of infl ammatory bowel disease and no family history of hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, or sporadic CRC; (v) eff ect estimates and the corresponding 95% confi dence intervals (CIs) were adjusted for age at least; and (vi) studies with an observational design (prospective cohort, retrospective cohort, or case-control studies). For studies with multiple publications from the same population source, only data from the most recent publication was included.
Data extraction and quality assessment
Two reviewers (J.P. and L.X.) extracted the data independently, and disagreements were resolved by consensus. Th e following data were extracted from each study: fi rst author, publication year, indications for index colonoscopy, study design, setting, study period, number of participants, age at baseline, sex, duration of follow-up, eff ect estimates with 95% CIs, and adjustments. For studies with several multivariable-adjusted estimates, we extracted those refl ecting the greatest degree of control for potential confounders. Th e primary outcomes were overall CRC incidence and mortality; the secondary outcomes were CRC incidence and mortality according to indications for colonoscopy, site of cancer, sex, and study design. Th e study quality was assessed using the Newcastle-Ottawa Scale ( 37 ) , and the studies awarded seven or more stars were considered of high quality.
Statistical analysis
Th e measure of eff ect of interest was the relative risk (RR). Odds ratio, rate ratio, risk ratio, or hazard ratio yielded similar estimates of RR ( 38 ) . Study-specifi c RR estimates were combined using a random-eff ects model, which considers both within-and between-study variation ( 39 ) . Statistical heterogeneity among studies was evaluated by I 2 and Q statistics ( 40 ) . Studies with an I 2 of <25%, 25-50%, 50-75%, and >75% were considered to have no, low, moderate, and high heterogeneity, respectively. An I 2 of >50% indicated signifi cant heterogeneity ( 41 ) . Sensitivity analysis was performed to evaluate the robustness of results, in which pooled estimates were computed omitting one study in each turn ( 42 ) . Subgroup analysis was performed by indications for colonoscopy, site of cancer, sex, and study design. We compared the pooled RR estimates from diff erent subgroups with a test of interaction ( 43 ) . Publication bias was evaluated by Begg's test and Egger's test ( 44, 45 ) . All statistical analyses were performed with Stata software, version 12.0 (Stata Corp, College Station, TX). P <0.05 was considered statistically signifi cant.
RESULTS
Literature search
PubMed and EMBASE were searched for relevant studies. As shown in Figure 1 , a total of 1,247 studies met our search strategy.
REVIEW
Colonoscopy and CRC Risk of Non-Malignant Findings
Aft er title/abstract review, we excluded 1,227 studies; aft er including 3 studies from reference review and 5 abstracts from DDW and UEGW, 28 studies remained. Another 17 studies were further excluded for reasons listed as follows: baseline population above average risk ( n =1) ( 46 ) , not all polyps removed ( n =1) ( 47 ) , eff ect estimates of interest not reported ( n =5) ( 17, (48) (49) (50) (51) , eff ect estimates of interest not adjusted ( n =1) ( 52 ), diff erent defi nition of outcome ( n =1) ( 53 ) , and same data source ( n =8) ( 25, 27, (54) (55) (56) (57) (58) (59) . Finally, 11 studies were included in the meta-analysis ( 18, 19, 28, 29, (60) (61) (62) (63) (64) (65) (66) .
Study characteristics and quality assessment
Details of the 11 included studies are listed in Table 1 . Of the 11 observational studies, 5 were cohort studies ( 18,60-63 ) (3 prospective ( 18,60,61 ) and 2 retrospective ( 62,63 )) and 6 were case-control studies ( 19, 28, 29, (64) (65) (66) . A total of 1,499,521 individuals were included, in which 1 study enrolled over 1,000,000 individuals ( 62 ), 7 studies enrolled 10,000-100,000 individuals each ( 18, 28, 60, 61, (63) (64) (65) , and the other 3 enrolled <10,000 individuals each ( 19, 29, 66 ) . Duration of follow-up for cohort studies (or corresponding duration from exposure of colonoscopy to CRC occurrence/death for case-control studies) varied, with three studies of over 10 years ( 18, 60, 61 ) , seven studies of 5-10 years ( 19, 28, 29, (62) (63) (64) (65) , and one study of <5 years ( 66 ) . Six studies reported CRC incidence only ( 19, 29, 61, 63, 64, 66 ) , four reported CRC mortality only ( 18, 28, 60, 65 ) , and one reported both CRC incidence and mortality ( 62 ). Indication(s) for index colonoscopy varied among studies, with screening in three studies ( 18, 19, 60 ) , screening/diagnostic in fi ve ( 28, 29, (61) (62) (63) , and diagnostic in three (64) (65) (66) . Eight studies were conducted in North America ( 18, 28, 29, 60, (62) (63) (64) (65) , and three in Europe ( 19, 61, 66 ) . In each of the 11 studies, colonoscopy at baseline (combination of polypectomy with removal of all detected lesions and negative colonoscopy) was compared with no colonoscopy.
Eff ect estimate of the study by Brenner et al. ( 19 ) was extracted from authors' reply letter in which a widely accepted defi nition of screening exposure was adopted ( 67, 68 ) . One study by Müller and Sonnenberg ( 64 ) separately reported eff ect estimates for colon and rectal cancer, and we included the combined RR by pooling the two estimates using a random-eff ect model.
Strategies for excluding CRC cases to form the group of patients with non-malignant fi ndings at the index colonoscopy varied among studies: two studies excluded CRC cases diagnosed at the index colonoscopy ( 64, 65 ) , four studies excluded CRC cases diagnosed at or within 6 months (exclusion window) of the index colonoscopy ( 28, 29, 63, 66 ) , one study used a longer exclusion window of 12 months ( 19 ) , three studies used variable exclusion windows ranging from 0 to 24 or 36 months ( 18, 60, 61 ) , and one study used a variable exclusion window ranging from 0 to 60 months ( 62 ) .
Results for study quality assessment are also shown in Table 1 (for details see Supplementary Appendices C and D ). Six out of the 11 studies were awarded seven or more stars, indicating high study quality. ( Table 3 ) 
DISCUSSION
Overview
Th is meta-analysis shows that CRC incidence and mortality in patients with non-malignant fi ndings were both 61% lower aft er colonoscopy. Th e protective eff ect was more prominent aft er screening colonoscopy, corresponding to an 89% reduction in CRC incidence.
Interpretations of study fi ndings
Our study is the fi rst meta-analysis to quantify the magnitude of protection against CRC that patients with non-malignant fi ndings benefi t from colonoscopy. When interpreting the study results, both the overall eff ect of colonoscopy and the individual
Primary outcomes
Seven studies were included for outcome of overall CRC incidence. Pooling by a random-eff ect model ( Figure 2 ) yielded a pooled RR of 0.39 (95% CI: 0.26-0.60), corresponding to a 61% RR reduction in CRC incidence aft er colonoscopy in patients with non-malignant fi ndings. Th ere was evidence of high heterogeneity among studies ( I 2 =93.6%, P <0.001). Sensitivity analysis revealed that the study by Brenner et al. ( 19 ) substantially infl uenced pooled RR. Aft er excluding this study, there was evidence of low heterogeneity ( I 2 =44.7%, P =0.11), and pooled RR was 0.51 (95% CI: 0.43-0.59). Funnel plot asymmetry test for publication bias was negative using both Begg's test ( P =0.07) and Egger's test ( P =0.43).
Five studies were included for outcome of overall CRC mortality. Pooling by a random-eff ect model ( Figure 3 ) yielded a pooled RR of 0.39 (95% CI: 0.35-0.43), corresponding to a 61% RR reduction in CRC mortality aft er colonoscopy in patients with non-malignant fi ndings. Th ere was no evidence of heterogeneity among studies ( I 2 =12.0%, P =0.34). Sensitivity analysis further confi rmed the robustness of our fi ndings. Funnel plot asymmetry test for publication bias was negative using both Begg's test ( P =0.22) and Egger's test ( P =0.35).
Secondary outcomes
Subgroup analyses were conducted for the following secondary outcomes of CRC incidence ( Table 2 ) . As for indications, screening colonoscopy was associated with greater protection (RR: 0.11; 95% CI: 0.08-0.15) than screening/diagnostic and diagnostic colonoscopies (RR: 0.51; 95% CI: 0.43-0.59; P interaction <0.001). As for site of cancer, colonoscopy was associated with a 28% nonstatistically signifi cant reduction in proximal CRC incidence (RR: 0.72; 95% CI: 0.50-1.03), whereas protection against distal CRC (RR: 0.32; 95% CI: 0.20-0.50) was much stronger ( P interaction =0.01). As for sex, results were similar for studies in men (RR: 0.55; eff ect of screening colonoscopy derived from subgroup analysis are informative. As regular colonoscopy screening has not been implemented even in many developed countries ( 20, 21 ) , the primary outcome, which estimated the benefi t derived from both screening and diagnostic colonoscopies, refl ected the eff ect of regular colonoscopy in routine clinical practice. Subgroup analysis of screening colonoscopy provides data on the maximum cases of CRCs and CRC-related deaths that may be prevented in patients with non-malignant fi ndings by population-based screening programs in standardized conditions, which is more important from a public health perspective.
Th ere are several explanations for our fi ndings. First, removal of all detected polyps (i.e., clearing colonoscopy) is the main modality responsible for the decreased CRC risk ( 69, 70 ) , while individuals with negative fi ndings are inherently associated with lower risks of developing CRC even compared with postpolypectomy individuals ( 71 ) . Second, interval CRCs could hardly be avoided because of factors such as missed lesions at the index colonoscopy, rapid growth of specifi c type of neoplasms, and incomplete resection of polyps ( 72 ) . Th erefore, both the aspects should be considered when interpreting the study fi ndings.
In subgroup analysis, our study showed more prominent protection against CRC incidence by screening colonoscopy than over screening/diagnostic and diagnostic colonoscopies on reducing CRC incidence. Th ird, with expanded colonoscopy indications (including both screening and diagnostic), study outcomes (including both incidence and mortality), and an updated inclusion of recent studies ( 18, 29 ) , our study ( n =1,499,521) is responsible for a more robust conclusion with a larger sample size.
Study limitations
Our study has several limitations. First, in addition to excluding detected CRCs (CRCs diagnosed at or within 6 months of the index colonoscopy) to arrive at non-malignant fi ndings at the index colonoscopy, fi ve of the eleven included studies also excluded interval CRCs (CRCs diagnosed within 6 to 36 (or even 60) months of the index colonoscopy) ( 18, 19, (60) (61) (62) . As interval CRCs certainly argue against the protective eff ect of colonoscopy ( 77, 78 ) , results of our study might be biased, causing overestimation of the magnitude of protection by colonoscopy. Th erefore, study results should be interpreted with caution. Second, it should be noted that indications for colonoscopy according to original publications of some studies may not refl ect real circumstances, e.g., studies by Nishihara et al. ( 18 ) and Eldridge et al. ( 60 ) initiated earlier than the nationwide introduction of screening colonoscopy. Th is may off er one of the explanations for the nonsignifi cant diff erence between the eff ect of screening vs. screening/ diagnostic and diagnostic colonoscopy on CRC mortality. Th ird, statistical heterogeneity was signifi cant for outcome of incidence. Th is might be explained by the diff erences in population enrolled, intervention strategy, and study designs. Aft er excluding the study by Brenner et al. ( 19 ) (screening was the only indication for colonoscopy), statistical heterogeneity became non-signifi cant.
Fourth, results of our study might be biased due to several other factors. Overestimation of the protective eff ect of colonoscopy might be caused by selection bias introduced by observational studies, e.g., participants in the colonoscopy (exposed) group tended to be more health-conscious ( 79 ), whereas underestimation of the colonoscopy with indications of screening/diagnostic and diagnostic ( P interaction <0.001), and, similar tendency was observed for CRC mortality (RR: 0.36 (0.29-0.46) vs. 0.40 (0.32-0.49); P interaction =0.51), as screening detects a diff erent spectrum of fi ndings (e.g., fewer polyps) compared with that diagnosed in the symptomatic population ( 35, 73, 74 ) . Our results showed that colonoscopy was less eff ective in preventing proximal CRC incidence and mortality (both P interaction <0.05) than distal CRC in patients with non-malignant fi ndings, which might be explained by several factors concerning endoscopists, patients, and tumor biology: proximal serrated polyps could be easily missed by endoscopists because of fl at or sessile appearance; patients' poor bowel preparation usually results in incomplete colonoscopy examination; diff erences in tumor biology exist between proximal and distal lesions of the colorectum ( 75, 76 ) .
Novelty of the study
Two previous meta-analyses are important studies on the eff ect of colonoscopy ( 30, 31 ) . Brenner et al. ( 30 ) found that screening colonoscopy is associated with 69 and 68% reductions in CRC incidence and mortality, respectively, and Elmunzer et al. ( 31 ) concluded that colonoscopy reduces CRC mortality by 57%. Novelty of our meta-analysis are threefold. First, in the two metaanalyses, patients with malignant fi ndings were enrolled in some included studies but not in others. Th e signifi cant heterogeneity of baseline population may strongly aff ect generalizability of their results in the general population. Th erefore, we enrolled in our meta-analysis patients with non-malignant fi ndings, a more homogeneous group constituting over 90% of the yield of colonoscopy in clinical practice ( 32, 33 ) and featured with non-malignant nature, mostly non-surgical treatment, longer surveillance interval, and better prognosis compared with malignant fi ndings ( 34, 35 ) . Second, the eff ect of screening colonoscopy and the eff ect of colonoscopy regardless of indication were separately reported in the two meta-analyses, without comparison, whereas our subgroup analysis found a more prominent eff ect of screening colonoscopy 
REVIEW
Colonoscopy and CRC Risk of Non-Malignant Findings results might be caused by contamination of the control (unexposed) group, e.g., individuals with adenomas in this group may present with symptoms and therefore receive colonoscopy examination with polypectomy ( 80 ) . Moreover, the initial age for screening in one study ( 18 ) is earlier than the guideline-recommended 50 years of age. In this sense, our results should be interpreted with caution, and randomized trials may better resolve this problem. Fift h, our study did not quantify individual CRC risk aft er either polypectomy or negative colonoscopy, as only one study by Nishihara et al. ( 18 ) reported eff ect estimates in subgroups of patients with polyps and those with negative fi ndings.
CONCLUSIONS
In conclusion, fi ndings from this meta-analysis of observational studies indicate that CRC incidence and mortality in patients with non-malignant fi ndings are signifi cantly reduced aft er colonoscopy, especially aft er screening colonoscopy. Th is provides additional evidence for the eff ectiveness of colonoscopy in the general population.
